RED HOT Contributors

 

STAT Plus: GSK’s new shingles vaccine may win nod over Merck’s Zostavax

0

O

ctober is shaping up to be a momentous month for GlaxoSmithKline’s new shingles vaccine, Shingrix.

The Food and Drug Administration may approve the vaccine for the U.S. market by the end of this week, based on a strong recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee. In mid-September, this group voted unanimously that there is enough evidence to conclude Shingrix is both safe and effective in people 50 and older.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It’s easy! Your first 30 days are free and if you don’t enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

About

We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast